A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma (original) (raw)

• Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759
  Article PubMed CAS Google Scholar
• Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410:439–453
  Article PubMed CAS Google Scholar
• Neckers L, Neckers K (2005) Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics—an update. Expert Opin Emerg Drugs 10:137–149
  Article PubMed CAS Google Scholar
• Workman P, Burrows F, Neckers L et al (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113:202–216
  Article PubMed CAS Google Scholar
• Powers MV, Workman P (2007) Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581:3758–3769
  Article PubMed CAS Google Scholar
• Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11(19 Pt 1):7023–7032
  Google Scholar
• Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P (2008) An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 62(5):769–778
  Google Scholar
• Solit DB, Zheng FF, Drobnjak M et al (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986–993
  PubMed CAS Google Scholar
• Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KM, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P (2007) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67(5):2206–2216
  Google Scholar
• Sharp SY, Prodromou C, Boxall K et al (2007) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 6:1198–1211
  Article PubMed CAS Google Scholar
• Banerji U, O’Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161
  Article PubMed CAS Google Scholar
• Solit DB, Ivy SP, Kopil C et al (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775–1782
  Article PubMed CAS Google Scholar
• Workman P (2003) Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2:131–138
  PubMed CAS Google Scholar
• Moreno-Farre J, Asad Y, Pacey S et al (2006) Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma. Rapid Commun Mass Spectrom 20:2845–2850
  Article PubMed CAS Google Scholar
• Pacey S, Walton M, Eisen T et al (2006) Validation and use of western blotting to measure pharmacodynamic endpoints in Cancer Research UK clinical trials of Heat Shock Protein (HSP90) inhibitors. Abstract A161. Presented at the NCRI meeting, Birmingham, UK
• Smith V, Sausville EA, Camalier RF et al (2005) Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56:126–137
  Article PubMed CAS Google Scholar
• Burger AM, Fiebig HH, Stinson SF et al (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377–387
  Article PubMed CAS Google Scholar
• Flaherty K, Puzanov I, Sosman J et al (2009) Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27:9000
  Google Scholar
• da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65(23):10686–10691
• Modi S, Stopeck AT, Gordon MS et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25:5410–5417
  Article PubMed CAS Google Scholar
• Davies H, Bignell GR, Cox C (2002) et al Mutations of the BRAF gene in human cancer. Nature 417:949–954
  Article PubMed CAS Google Scholar
• Banerji U, Affolter A, Judson I, Marais R, Workman P (2008) BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7(4):737–739
  Google Scholar
• Nowakowski GS, McCollum AK, Ames MM et al (2006) A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087–6093
  Article PubMed CAS Google Scholar
• Gelmon KA, Eisenhauer EA, Harris AL et al (1999) Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91:1281–1287
  Article PubMed CAS Google Scholar
• Michaelis LC, Ratain MJ (2007) Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 13:2400–2405
  Article PubMed Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166
  PubMed CAS Google Scholar
• Richards JM, Gale D, Mehta N et al (1999) Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17:651–657
  PubMed CAS Google Scholar
• Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634
  PubMed CAS Google Scholar
• Manola J, Atkins M, Ibrahim J et al (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782–3793
  PubMed CAS Google Scholar
• Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastatic melanoma: time for a change? Cancer 109:455–464
  Article PubMed CAS Google Scholar
• Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10
  Article PubMed CAS Google Scholar
• Therasse P (2002) Evaluation of response: new and standard criteria. Ann Oncol 13(Suppl 4):127–129
  PubMed Google Scholar
• Egorin MJ, Zuhowski EG, Rosen DM et al (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291–302
  Article PubMed CAS Google Scholar
• Kamal A, Thao L, Sensintaffar J et al (2003) et al A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410
  Article PubMed CAS Google Scholar
• Chung YL, Troy H, Banerji U et al (2003) Magnetic Resonence Spectroscopic Pharmacodynamic Markers of the Heat Shock Protien Inhibitor 17-Allyamino, 17-Demethoxygeldanamycin (17-AAG) in Human Colon Cancer Models. J Natl Cancer Inst 95:1624–1633
  Article PubMed CAS Google Scholar
• Smith-Jones PM, Solit D, Afroze F et al (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793–796
  PubMed CAS Google Scholar
• Taldone T, Gozman A, Maharaj R et al (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8:370–374
  Article PubMed CAS Google Scholar
• Kefford R, Millwars M, Hersey P et al (2007) Phase 2 Trial of Tanespimycin (KOS-953), a Heat Shock Protein-90 (Hap90) Inhibitor in Patients with Metastatic Melanoma. J Clin Oncol 25:8558
  Google Scholar
• Pacey S, Wilson R, Walton M et al (2007) A Phase I Trial Of The Heat Shock Protein 90 (HSP90) Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG, Alvespimycin) Administered Weekly. J Clin Oncol 25
• Flaherty KT, Gore L, Avadhani A et al (2008) First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD. J Clin Oncol 26:2502
  Google Scholar
• Solit DB, Osman I, Polsky D et al (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14:8302–8307
  Article PubMed CAS Google Scholar
• Korn EL, Liu PY, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527–534
  Article PubMed Google Scholar
• Elfiky A, Saif MW, Beeram M et al (2008) BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 26:2503
  Google Scholar
• Sessa C, Sharma SK, Britten CD et al (2009) A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 27:3532
  Google Scholar
• Bryson JC, Infante JR, Ramanathan RK et al (2008) A phase 1 dose-escalation study for the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-4522. J Clin Oncol 26:14613
  Google Scholar
• Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8):2850–2860
  Google Scholar